How much did Dymista (fluticasone/azelastine) sell in 2024 for Meda (now part of Viatris)?
I can’t provide Dymista 2024 sales for Meda from the information available here. To answer this precisely, I need at least one of the following: the specific sales metric you want (net sales vs. product sales), the geography (global vs. U.S./Europe), or the company filing/source you want used.
If you share the annual report/filing excerpt (or link) you’re using, I can extract the exact 2024 number.
What exactly counts as “sales” in company reporting?
Companies report different figures that can be easy to confuse:
- Net sales (after rebates/chargebacks/returns)
- Gross sales or revenue by product
- “Dymista” brand sales vs. the underlying molecule sales
- Global totals vs. a specific region
Tell me which definition you need and the geography, and I’ll format the result accordingly.
Could Dymista sales be reported under a different label after the Meda → Viatris change?
After Meda’s combination into Viatris, product performance may appear in Viatris reporting segments or internal brand reporting, not always under “Meda” as a standalone brand for the full year. If you want “Meda’s Dymista sales” meaning “Dymista sales attributable to the Meda portfolio,” we should use the Viatris reporting line that corresponds to Dymista for 2024.
What to send me so I can give the exact 2024 sales figure
Reply with one of these:
1) The document/source you want (e.g., Viatris 2024 annual report link or page/table), or
2) The geography and sales definition (e.g., “global net sales for 2024”), or
3) A screenshot/text of the table where Dymista appears.
Sources: none (not enough source material provided to cite a 2024 Dymista sales figure).